| Methods |
Random allocation (computer generated random numbers block design)
Method of concealment not stated |
| Participants |
Psoriasis, arthritis, partial response to NSAIDs, >3 joints, could be seropositive
Multicentre design (USA and Canada)
N=238
Mean age 44, median duration of arthritis 5 years |
| Interventions |
Auranofin 3mg/day versus identical placebo |
| Outcomes |
All Omeract 1 outcomes
24 weeks duration |
| Notes |
Only three outcomes could be included even after communication with authors due to nature of outcomes (some categorical which meant means and SDs could not be calculated)
21% withdrew |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A ‐ Adequate |
